Press Releases

April 04, 2019 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate at the World Vaccine Congress Washington being held in Washington, D.C.

February 28, 2019 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that a poster will be presented by Immunomic scientists at the American Association for Cancer

Immunomic Therapeutics to Sponsor and Present at CHCI Health Summit February 26, 2019 04:05 PM Eastern Standard Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its’ Senior Vice

  February 06, 2019 05:00 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company has granted Japanese animal

January 24, 2019 04:05 PM Eastern Standard Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its’ founder and CEO, William Hearl, Ph.D., will present an overview of the

November 15, 2018 06:15 AM Eastern Standard Time SAN DIEGO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) announced today that the company will present and participate at the 2018 World Vaccine & Immunotherapy

November 07, 2018 06:00 AM Eastern Standard Time NEW ORLEANS--(BUSINESS WIRE)--On Friday, November 16, Immunomic Therapeutics Inc. (ITI) Scientist Amit Adhikara will present at the Society for NeuroOncology 2018 Annual

Immunomic Therapeutics Senior Director of Corporate Development to Present at Precision Lung Cancer World R&D Summit Discussion of lysosomal targeting technology as applied in cancer immunotherapy October 26, 2018 07:30

Immunomic Therapeutics CEO to Present at NYC Oncology Investor Conference To Discuss UNITE Technology Application in Oncology October 23, 2018 07:00 AM Eastern Daylight Time   NEW YORK--(BUSINESS WIRE)--Immunomic Therapeutics,

Panel to Highlight Advanced Therapeutics for Oncology October 03, 2018 12:00 AM Eastern Daylight Time BASEL, Switzerland--(BUSINESS WIRE)--Tomorrow, William Hearl, Ph.D., Chief Executive Officer (CEO) of Immunomic Therapeutics, Inc., will

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company presented at the 2018 BIO Investor Forum held in San Francisco, CA on October 17-18. William Hearl, Ph.D., Immunomic’s Founder

ITI Founder & CEO will discuss new developments in cancer immunotherapy October 01, 2018 05:02 PM Eastern Daylight Time ROCKVILLE, Md. (BUSINESSWIRE)--Bill Hearl, Ph.D., Founder and Chief Executive Officer (CEO)